Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

In this cohort study, outcomes with Lu-177 PSMA were broadly consistent across treatment lines and taxane sequencing groups. These findings may help inform patient counseling, although prospective studies are needed to determine the optimal treatment sequencing strategy.

Corresponding Authors: Umang Swami, MD, MS (umang.swami@hci.utah.edu), and Neeraj Agarwal, MD (neeraj.agarwal@hci.utah.edu), University of Utah Health Huntsman Cancer Institute, 2000 Circle of Hope Dr, Ste 5510, Salt Lake City, UT 84112.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.